Tuttle: AVGO 'Almost Needs Cure for Cancer' to Justify Valuation

Matt Tuttle considers Broadcom (AVGO) a "must own" A.I. chip stock, alongside Nvidia (NVDA). He'll focus on the company's margins and VMware, believing they serve as indicators for Broadcom's future growth. That said, Matt is nervous when it comes to valuation, arguing that Broadcom "almost needs to have a cure for cancer" for the stock to push higher. Tom White offers a pair of example options trades for the chipmaker.

Morning Trade Live

04 Sep 2025

SHARE

ON AIR
1:30 pm
The Wrap
replay
12:00 am
Market Overtime
REPLAY
12:30 am
Market On Close
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
education
5:00 am
Liz Ann Live
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Market Overtime
REPLAY
8:00 am
Market Overtime
REPLAY
8:30 am
Market On Close
REPLAY
education
10:00 am
Schwab 2026 Outlook
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Liz Ann Live
REPLAY
ON AIR
1:30 pm
The Wrap
REPLAY
3:00 pm
Market Overtime
REPLAY
4:00 pm
Market Overtime
REPLAY
4:30 pm
Market On Close
REPLAY
education
6:00 pm
Schwab 2026 Outlook
REPLAY
7:00 pm
Fast Market
REPLAY
8:00 pm
Next Gen Investing
REPLAY
education
9:00 pm
Liz Ann Live
REPLAY
9:30 pm
The Wrap
REPLAY
11:00 pm
Market Overtime
REPLAY

Schwab Network's Newsletters

Daily insights for every investor